Table 2.
Clinical-pathological features of BRCAness-tested patients
| BRCAness N (%) | Non-BRCAness N (%) | |
|---|---|---|
| Total patients | 10 (15.8) | 53 (84.1) |
| Age (years) | ||
| <40 | 3 (4.7) | 46 (73) |
| >40 | 7(11.1) | 4 (6.3) |
| NA | 3 (4.7) | |
| Stage* | ||
| I | 1 (1.5) | 24 (38) |
| II | 8 (12.6) | 14 (22.2) |
| II | 1 (1.5) | 13 (20.6) |
| NA | 2 (3.1) | |
| Tumor grade | ||
| I | 0 (0) | 9 (14.2) |
| II | 3 (4.7) | 23 (36.5) |
| III | 7(11.1) | 19 (30.1) |
| NA | 2 (3.1) | |
| Nuclear pleomorfism | ||
| I | 0 (0) | 6 (9.5) |
| II | 1 (1.5) | 25 (39.6) |
| III | 9 (14.2) | 20 (31.7) |
| NA | 2 (3.1) | |
| Molecular subtypes | ||
| Luminal A | ||
| Positive | 1 (1.5) | 10 (15.8) |
| Negative | 9 (14.2) | 42 (66.6) |
| NA | 1 (1.5) | |
| Luminal B | ||
| Positive | 4 (6.3) | 23 (36.5) |
| Negative | 6 (9.5) | 29 (46) |
| NA | 1 (1.5) | |
| HER2+ | ||
| Positive | 0(0) | 5 (7.9) |
| Negative | 9 (14.2) | 47 (74.6) |
| NA | 1 (1.5) | 1 (1.5) |
| TN | ||
| Positive | 6 (9.5) | 10 (15.8) |
| Negative | 4 (6.3) | 41 (65) |
| NA | 0(0) | 2 (3.1) |
*
Stage according to AJCC (American Joint Committee on Cancer)